logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
S

Song Xue

北京大学深圳医院
H指数:29
被引数:3,167

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Total-body 11C-PIB PET/CT imaging of systemic amyloidosis: inter-organ connectivity in cardiac amyloidosis for prognostic insights

全身11C-PIB PET/CT成像在系统性淀粉样变性中的应用：基于心脏淀粉样变性的器官间连通性对预后评估的启示

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
IF7.6
2025-05-050
OA
Hong, Zhihui; Xue, Song; Yu, Josef; Calabretta, Raffaella; Haberl, David; Jiang, Zewen; Gruenert, Stefan; Beitzke, Dietrich; Kammerlander, Andreas; Hacker, Marcus; Li, Xiang
Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and bevacizumab for epidermal growth factor receptor inhibitor (EGFRi)-resistant, EGFR-mutant, advanced non-small cell lung cancer (NSCLC): Updated results from Cohort 5 in the DUBHE-L-201 study

伊帕罗利单抗和图沃纳利单抗（QL1706）联合化疗和贝伐珠单抗，用于表皮生长因子受体抑制剂（EGFRi）耐药、EGFR突变、晚期非小细胞肺癌（NSCLC）：DUBHE-L-201研究中Cohort 5的更新结果

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Fang, W. F.; Yang, Y.; Zhao, Y.; Huang, Y.; Zhao, H.; Zhou, N.; Zhang, Y.; Chen, L.; Zhou, T.; Chen, G.; Li, H.; Wu, T.; Xue, S.; Kang, X.; Zhang, L.
First-line iparomlimab and tuvonralimab (QL1706) + chemotherapy (chemo) ± bevacizumab (BEV) for recurrent or metastatic cervical cancer (r/mCC): Updated results of the phase II DUBHE-C-204 study

伊帕罗利单抗（iparomlimab）和图沃纳利单抗（tuvonralimab，QL1706）联合化疗（chemo）±贝伐珠单抗（BEV）治疗复发性或转移性宫颈癌（r/mCC）：DUBHE-C-204 II期研究的更新结果

ANNALS OF ONCOLOGY
IF65.4
2024-12-011
PRE
Liu, N.; Yang, Z.; Tang, D.; Lou, H.; Zhang, K.; Cao, H.; Zou, D.; Zhang, X.; Xue, S.; Kang, X.; Wang, D.

研究方向

暂未获取到该数据
W
Weilin Sang
H 指数:14论文数:55被引数:831
J
Jinzhong Ma
H 指数:13论文数:61被引数:734
C
Changhai Ding
H 指数:72论文数:688被引数:1.9万
L
Libo Zhu
H 指数:24论文数:158被引数:1,971
H
Haiming Lu
H 指数:13论文数:49被引数:804
G
Guangfeng Ruan
H 指数:21论文数:122被引数:1,378
Y
Yiming Xu
H 指数:16论文数:88被引数:1,215
Y
Yafei Jiang
H 指数:23论文数:85被引数:2,246
Y
Yiming Zhong
H 指数:12论文数:75被引数:968
C
Cong Wang
H 指数:19论文数:116被引数:1,810